UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
For the three-month periods ended September 30, 2026 and 2025 Consolidated Statements of Financial Position(Unaudited - Expressed in Canadian dollars) | As at September 30, 2026 $ | As at June 30, 2026 $ |
Assets | ||
Current assets | ||
Cash and cash equivalents | 23,517,890 | 25,048,438 |
Accounts receivable and contract asset | 27,960,000 | 33,057,368 |
Inventory | 16,744,575 | 16,666,846 |
Prepaid expenses and other assets | 1,997,555 | 1,650,236 |
70,220,020 | 76,422,888 | |
Non-current assets | ||
Lease deposits | 303,317 | 303,114 |
Right-of-use assets [Note 3a] | 20,313,859 | 18,546,208 |
Property, plant and equipment [Note 3b] | 74,614,041 | 74,681,645 |
Intangible assets [Note 4] | 10,524,747 | 10,935,678 |
Goodwill | 1,919,673 | 1,919,673 |
Deferred tax assets | 5,324,418 | 4,722,107 |
Total assets | 183,220,075 | 187,531,313 |
Liabilities and Shareholders' Equity | ||
Current liabilities | ||
Operating loans | 680,240 | 703,080 |
Accounts payable and accrued liabilities | 18,623,245 | 20,509,619 |
Income taxes payable | 243,340 | 82,759 |
Contract liability | 594,383 | 441,636 |
Current portion of lease liability [Note 5] | 5,369,328 | 4,896,438 |
Current portion of long-term debt [Note 5] | 2,788,212 | 2,963,826 |
28,298,748 | 29,597,358 | |
Non-current liabilities | ||
Defined benefit liabilities | 434,920 | 541,588 |
Lease liability [Note 5] | 33,055,984 | 32,279,767 |
Long-term debt [Note 5] | 7,032,006 | 7,590,609 |
Deferred tax liabilities | 4,122,692 | 4,073,815 |
Total liabilities | 72,944,350 | 74,083,137 |
Shareholders' equity | ||
Share capital [Note 6] | 207,510,956 | 207,510,956 |
Reserve | 8,660,164 | 8,408,536 |
Foreign currency translation reserve | (361,989) | (382,374) |
Deficit | (105,533,406) | (102,088,942) |
Total shareholders' equity | 110,275,725 | 113,448,176 |
Total liabilities and shareholders' equity | 183,220,075 | 187,531,313 |
See accompanying notes to consolidated financial statements
Approved on behalf of the Board of Directors
Rocco Marinaccio
Rocco Marinaccio
Jos eph G. Peter
Joseph G. Peter
Consolidated Statements of Los s and Comprehensive LossThree-month periods ended September 30,
(Unaudited - Expressed in Canadian dollars) | 2026 $ | 2025 $ |
Revenues Revenues from customers Other income | 31,160,777 653,036 | 22,986,917 455,734 |
31,813,813 | 23,442,651 | |
Cost of sales and expenses | ||
Cost of sales | 24,397,364 | 19,021,547 |
Research and development expenses | 1,172,336 | 1,211,423 |
Selling, general and administrative expenses | 5,552,453 | 4,639,782 |
Share-based compensation expenses | 251,628 | 204,546 |
Depreciation (production) | 2,159,993 | 1,773,312 |
Depreciation (other) | 703,823 | 707,635 |
Amortization | 478,435 | 474,369 |
Foreign exchange | 284,663 | (233,948) |
35,000,695 | 27,798,666 | |
Operating loss | (3,186,882) | (4,356,015) |
Interest on operating loans and long-term debt | (155,241) | (54,733) |
Interest accretion on lease liability | (644,566) | (348,309) |
Interest revenue | 103,776 | 66,231 |
Loss before income taxes | (3,882,913) | (4,692,826) |
Current income tax expense | (52,748) | (37,999) |
Deferred income tax recovery | 400,368 | 954,495 |
347,620 | 916,496 | |
Loss | (3,535,293) | (3,776,330) |
Other comprehensive income (loss) Items that may be subsequently reclassified to profit and loss: Exchange differences on translation of foreign subsidiaries | 20,385 | (192,193) |
Items that will not be reclassified to profit and loss: Retirement benefits - Net actuarial gain (loss) | 90,829 | 132,105 |
Total comprehensive loss | (3,424,079) | (3,836,418) |
Loss per share | ||
Basic and diluted | (0.02) | (0.02) |
Weighted average number of common shares outstanding (basic and diluted) | 181,487,392 | 170,608,431 |
In light of the loss recognized for the periods, stock options were excluded from the calculation of diluted loss per share due to their anti-dilutive effect.
See accompanying notes to consolidated financial statements
Consolidated Statements of Changes in Shareholders' Equity
(Unaudited - Expressed in Canadian dollars) | Number of common shares | Share capital $ | Reserve $ | Foreign currency translation reserve $ | Deficit $ | Shareholders' equity $ |
Balance as at June 30, 2025 | 170,608,431 | 182,683,203 | 7,290,752 | 95,323 | (90,714,156) | 99,355,122 |
Loss | - | - | - | - | (3,776,330) | (3,776,330) |
Other comprehensive loss | - | - | - | (192,193) | 132,105 | (60,088) |
Comprehensive loss | - | - | - | (192,193) | (3,644,225) | (3,836,418) |
Exercise of stock options | - | |||||
Share-based compensation | - | - | 204,546 | - | - | 204,546 |
Balance as at September 30, 2025 | 170,608,431 | 182,683,203 | 7,495,298 | (96,870) | (94,358,381) | 95,723,250 |
Loss | - | - | - | - | (8,051,651) | (8,051,651) |
Other comprehensive income (loss) | - | - | - | (285,504) | 321,090 | 35,586 |
Comprehensive loss | - | - | - | (285,504) | (7,730,561) | (8,016,065) |
Private placement (net of issuing costs of $1,441,343) | 10,720,350 | 24,287,497 | - | - | - | 24,287,497 |
Exercise of stock options | 158,611 | 540,256 | (186,256) | - | - | 354,000 |
Share-based compensation | - | - | 1,099,494 | - | - | 1,099,494 |
Balance as at June 30, 2026 | 181,487,392 | 207,510,956 | 8,408,536 | (382,374) | (102,088,942) | 113,448,176 |
Loss | - | - | - | - | (3,535,293) | (3,535,293) |
Other comprehensive income | - | - | - | 20,385 | 90,829 | 111,214 |
Comprehensive loss | - | - | - | 20,385 | (3,444,464) | (3,424,079) |
Exercise of stock options | - | - | - | - | - | - |
Share-based compensation | - | - | 251,628 | - | - | 251,628 |
Balance as at September 30, 2026 | 181,487,392 | 207,510,956 | 8,660,164 | (361,989) | (105,533,406) | 110,275,725 |
See accompanying notes to consolidated financial statements |
3
Consolidated Statements of Cash FlowsThree-month periods ended September 30,
(Unaudited - Expressed in Canadian dollars) | 2026 $ | 2025 $ |
Cash flows from operating activities | ||
Loss | (3,535,293) | (3,776,330) |
Items not affecting cash: Depreciation and amortization | 3,342,251 | 2,955,316 |
Share-based compensation expenses | 251,628 | 204,546 |
Interest accretion on lease liability | 644,566 | 348,309 |
Interest accretion on long-term debt | 8,489 | 14,478 |
Deferred income tax recovery | (400,368) | (954,495) |
Difference between amounts paid for employee benefits and current year expenses | 1,755 | 6,015 |
Net change in fair value of foreign exchange derivatives | 52,482 | 530,386 |
Unrealized foreign exchange | (512,505) | (225,169) |
Changes in non-cash operating working capital items: Accounts receivable and contract asset | 4,522,561 | 799,509 |
Inventory | (123,841) | (299,536) |
Prepaid expenses and other assets | (351,719) | (364,969) |
Accounts payable and accrued liabilities | (2,679,567) | (5,209,901) |
Income taxes payable | 160,581 | 17,734 |
Contract liability | 152,747 | (265,553) |
1,533,767 | (6,219,660) | |
Cash flows from financing activities | ||
Variation of operating loans | - | (174,655) |
Issuance of long-term debt | - | 3,175,000 |
Repayment of lease liability | (1,959,512) | (1,078,322) |
Repayment of long-term debt | (740,306) | (542,370) |
(2,699,818) | 1,379,653 | |
Cash flows from investing activities | ||
Additions to intangible assets | (52,797) | (542,361) |
Additions to property, plant and equipment | (265,876) | (3,137,450) |
(318,673) | (3,679,811) | |
Change in cash and cash equivalents | (1,484,724) | (8,519,818) |
Net effect of currency exchange rate on cash | (45,824) | 23,782 |
Cash and cash equivalents, beginning of year | 25,048,438 | 18,587,960 |
Cash and cash equivalents, end of year | 23,517,890 | 10,091,924 |
Interest on operating loans, long-term debt and lease liability paid | 799,807 | 403,042 |
Additions to property, plant and equipment included in accounts payable and accrued liabilities | 621,550 | 165,762 |
Additions to property, plant and equipment paid with equipment deposits | - | 674,414 |
Investment tax credit recorded against the property, plant and equipment and included in accounts receivable and contract asset | 242,977 | - |
See accompanying notes to consolidated financial statements
[Unaudited - Unless specified otherwise, amounts are expressed in Canadian dollars]
- NATURE OF OPERATIONS
NanoXplore is a graphene company and the largest manufacturer and supplier of high-volume graphene powder for use in multiple end markets with up to 5,000 tonnes of annual production capacity. The Corporation also provides standard and custom graphene-enhanced plastic and composite products to customers in the recreational vehicle, transportation, packaging, electronics, and other industrial sectors, and manufactures silicon-graphene-enhanced Li-ion batteries for the energy storage, industrial, and defense markets. NanoXplore holds over 100 patents and patent applications protecting its intellectual property, products, and process knowledge, and is one of a limited number of companies authorized to produce and sell graphene at commercial scale in Canada, the United States, the United Kingdom, and the European Union, holding Environment and Climate Change Canada (ECCC) and Health Canada certification, U.S. EPA certification, and UK and EU REACH registrations.
The Corporation was formed by amalgamation under the Canada Business Corporations Act by certificate of amalgamation dated September 21, 2017 and is headquartered at 4500 Thimens Blvd, Montreal, QC, Canada.
NanoXplore is listed on the Toronto Stock Exchange ("TSX") and traded under "GRA" and is also listed on the OTCQX and traded under "NNXPF".
The Corporation has two reportable segments based on products: Advanced Materials, Plastics and Composite Products and Battery Cells and Materials [Note 9].
The unaudited condensed interim consolidated financial statements of the Corporation for the three-month periods ended September 30, 2026 and 2025 were reviewed, approved and authorized for issue by the Corporation's Board of Directors on November 10, 2026.
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
The unaudited condensed interim consolidated financial statements of the Corporation and its subsidiaries for the three-month periods ended September 30, 2026 and 2025 have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS accounting standards"), and applicable to the preparation of interim financial statements including IAS 34, Interim Financial Reporting.
These unaudited condensed interim consolidated financial statements are presented in Canadian dollars, the Corporation's functional currency, except where otherwise indicated. Each entity of the Corporation determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.
The significant accounting judgments, estimates and assumptions used in these unaudited condensed interim consolidated financial statements are consistent with those disclosed in the most recent audited annual consolidated financial statements for the year ended June 30, 2026.
These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, at historical cost, except for financial assets and liabilities classified as financial assets/liabilities at fair value through profit or loss and measured at fair value. Management considers that the fair value of financial assets and liabilities recorded in the financial statements approximates the carrying amount.
Basis of consolidationThe unaudited condensed interim consolidated financial statements include the accounts of the Corporation and its subsidiaries. The subsidiaries are using consistent accounting policies and the same reporting period as the parent company. All intercompany transactions, balances and unrealized gains or losses have been eliminated.
The Corporation has the following subsidiaries:
Standards, interpretations and amendments to published standards adopted with an effect on the unaudited condensed interim consolidated financial statementsSubsidiaries
Reporting segment
CEBO Injections SA ("CEBO"), based in Switzerland, with an equity interest of 100% [2025 - 100%]
Advanced Materials, Plastics and Composite Products
NanoXplore Holdings USA, Inc. ("NanoXplore Holdings USA"), based in the United States, with an equity interest of 100% [2025 - 100%]. NanoXplore Holdings USA holds 100% of NanoXplore USA, Inc. and of RMC Advanced Technologies Inc. [2025 - 100%].
Advanced Materials, Plastics and Composite Products
Sigma Industries Inc. ("Sigma"), based in Canada, with an equity interest of 100% [2025 - 100%]. Sigma has two active wholly owned subsidiaries; Faroex Ltd., based in Manitoba, and Rene Composite Materials Ltd., based in Quebec. [2025 - 100%]
Advanced Materials, Plastics and Composite Products
Canuck Compounders Inc. ("Canuck"), [2025 - 100%]
based in Canada,
with an equity interest of 100%
Advanced Materials,
Plastics and Composite Products
VoltaXplore Inc. ("VoltaXplore"), based in Canada, with an equity interest of 100% [2025 - 100%]
Battery Materials
Cells
and
The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements. The unaudited condensed interim consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes for the year ended June 30, 2026.
For the three-month period ended September 30, 2026, the Management evaluated the new accounting standards and interpretations issued and effective under IFRS Accounting Standards and determined that they have no material impact on its consolidated financial statements.
The following standards and amendments to existing standards have been published, and their adoption is mandatory for future accounting periodsThe IASB has issued new standards and amendments to existing standards which are applicable to the Corporation in future periods.
IFRS 18 - Presentation and Dis clos ure in Financial Statements
On April 9, 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements to improve reporting of financial performance. IFRS 18 replaces IAS 1 Presentation of Financial Statements. It carries forward many requirements from IAS 1 unchanged. IFRS 18 applies for annual reporting periods beginning on or after January 1, 2027. Earlier application is permitted.
The new Accounting Standard introduces significant changes to the structure of a corporation's income statement and new principles for aggregation and disaggregation of information. The main impacts of the new Accounting Standard include:
introducing a newly defined "operating profit" subtotal and a requirement for all income and expenses to be allocated between three distinct categories based on the company's main business activities: Operating, investing and financing;
disclosure about management performance measures; and,
adding new principles for aggregation and disaggregation of information.
requiring the cash flow statement to start with operating profit; and
removal of the accounting policy choice for presentation of dividend and interest. Management has not yet determined the impact, if any, for the Corporation.
- PROPERTY, PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS
Three-month
period ended September 30, 2026
$
Year ended June 30, 2026
$
18,546,208
6,130,403
2,669,195
15,209,899
(911,753)
(3,184,003)
10,209
389,909
20,313,859
18,546,208
34,109,430
31,430,026
(13,795,571)
(12,883,818)
20,313,859
18,546,208
RIGHT-OF-USE ASSETS
Additions Depreciation
Effect of foreign exchange differences
Balance at the endBalance at the end
Cost
Accumulated amortization
Net book valueThe majority of right-of-use assets are leases of land and building.
b) PROPERTY, PLANT AND EQUIPMENT | |||||
Land & | Production | Leasehold | Laboratory, computer, office equipment and | ||
Building | equipment | improvements | rolling stock | Total | |
$ | $ | $ | $ | $ | |
Balance as at July 1, 2025 | 11,126,175 | 44,299,725 | 2,310,736 | 7,872,842 | 65,609,478 |
Additions | 236,653 | 15,113,407 | 99,537 | 264,471 | 15,714,068 |
Disposals | - | - | - | - | - |
Depreciation | (535,677) | (4,744,665) | (432,086) | (1,605,979) | (7,318,407) |
Effect of foreign exchange differences | - | 670,441 | 5,000 | 1,065 | 676,506 |
Balance as at June 30, 2026 | 10,827,151 | 55,338,908 | 1,983,187 | 6,532,399 | 74,681,645 |
Additions | 37,114 | 917,558 | 33,785 | 179,117 | 1,167,574 |
Depreciation | (129,899) | (1,301,453) | (119,539) | (401,172) | (1,952,063) |
Effect of foreign exchange differences | - | 716,885 | - | - | 716,885 |
Balance as at September 30, 2026 | 10,734,366 | 55,671,898 | 1,897,433 | 6,310,344 | 74,614,041 |
As at June 30, 2026 Cost | 13,845,677 | 83,253,963 | 4,330,739 | 13,732,514 | 115,162,893 |
Accumulated depreciation | (3,018,526) | (27,915,055) | (2,347,552) | (7,200,115) | (40,481,248) |
Net book value | 10,827,151 | 55,338,908 | 1,983,187 | 6,532,399 | 74,681,645 |
As at September 30, 2026 Cost | 13,347,114 | 80,129,808 | 3,933,938 | 12,305,971 | 109,716,831 |
Accumulated depreciation | (2,612,748) | (24,457,910) | (2,036,505) | (5,995,627) | (35,102,790) |
Net book value | 10,734,366 | 55,671,898 | 1,897,433 | 6,310,344 | 74,614,041 |
The majority of property, plant and equipment is pledged as security for the credit facilities (Note 5).
Additions of production equipment under lease during the three-month period ended September 30, 2026 amounted to nil [year ended June 30, 2026 - $7,142,265].
As at September 30, 2026, there are $37,114, $2,797,745 and $507,894 of building, production equipment and computer. respectively, that are not yet available for use and for which depreciation has not started [As at June 30, 2026 - $206,298,
$7,866,462 and $492,554].
4. | INTANGIBLE ASSETS | ||||
Customer relationship | Technology | Patents, licenses and software | Total | ||
$ | $ | $ | $ | ||
Balance as at July 1, 2025 | 3,922,235 | 5,183,939 | 2,853,317 | 11,959,491 | |
Additions | - | - | 873,762 | 873,762 | |
Amortization | (841,388) | (668,895) | (406,077) | (1,916,360) | |
Effect of foreign exchange differences | 2,074 | - | 16,711 | 18,785 | |
Balance as at June 30, 2026 | 3,082,921 | 4,515,044 | 3,337,713 | 10,935,678 | |
Additions | - | - | 52,797 | 52,797 | |
Amortization | (210,135) | (167,224) | (101,076) | (478,435) | |
Effect of foreign exchange differences | (1,503) | - | 16,210 | 14,707 | |
Balance as at September 30, 2026 | 2,871,283 | 4,347,820 | 3,305,644 | 10,524,747 | |
As at June 30, 2026 Cost | 8,594,454 | 6,688,953 | 4,975,308 | 20,258,715 | |
Accumulated depreciation | (5,511,533) | (2,173,909) | (1,637,595) | (9,323,037) | |
Net book value | 3,082,921 | 4,515,044 | 3,337,713 | 10,935,678 | |
As at September 30, 2026 Cost | 8,592,951 | 6,688,953 | 5,044,315 | 20,326,219 | |
Accumulated depreciation | (5,721,668) | (2,341,133) | (1,738,671) | (9,801,472) | |
Net book value | 2,871,283 | 4,347,820 | 3,305,644 | 10,524,747 | |
As at September 30, 2026, there is $104,895 of software that is not yet available for use and for which amortization has not started [As at June 30, 2026 - $91,961].
Maturity | Effective interest rate % | As at September 30, 2026 $ | As at June 30, 2026 $ |
2026 to 2027 | 3.6% | 680,240 | 703,080 |
2026 to 2035 | 2.4% to 8.4% | 38,425,312 | 37,176,205 |
2027 to 2036 | 4.6% to 7.9% | 9,820,218 | 10,554,435 |
48,925,770 | 48,433,720 | ||
680,240 | 703,080 | ||
5,369,328 | 4,896,438 | ||
2,788,212 | 2,963,826 | ||
40,087,990 | 39,870,376 | ||
- CREDIT FACILITIES
Operating loans, fixed and variable rates
- Authorized amount of $10,693,184
Lease liabilityLong-term debt, fixed and variable rates
Less: current portion of operating loans Less: current portion of lease liability Less: current portion of long-term debt
Under these agreements, the Corporation has agreed to respect certain conditions and financial ratios. As at September 30, 2026, all conditions and financial ratios were met. Several movable hypothecs on specific assets of the Corporation and its subsidiaries and on the universality of the Corporation's present and future, tangible and intangible assets have been given as security for these long-term debt and credit facilities.
LEASE LIABILITY
As at September 30, 2026
$
As at June 30, 2026
$
14,357,644
24,067,668
15,145,046
22,031,159
38,425,312
37,176,205
The Corporation has the following leases related to equipment and building:
Equipment [Note 3a, 3b] Building [Note 3a]
Total lease liability
- EQUITY
On October 30, 2025, the Corporation completed a financing by way of a bought deal private placement of 10,720,350 common shares at a price of $2.40 per share for gross proceeds of $25,728,840. The aggregate issuance costs related to this issuance, including the commission, were $1,441,343 and paid in cash.
During the year ended June 30, 2026, 1,580,043 options were granted. These options have an exercise price between $2.09 and $2.43 with a vesting period between one year and three years and a half and expiration date between five and ten years from the grant date. The exercise price is based on the share price the day prior to the grant.
During the year ended June 30, 2026, 158,611 options were exercised resulting in cash proceeds of $354,000 and a transfer from "Reserve" to "Share capital" of $186,256. The weighted average share price on the date of exercise of the options was
$2.64.
During the three-month period ended September 30, 2026, 200,000 options were granted. These options have an exercise price of $1.37 and $1.46 with a vesting period between one year and three years and a half and expiration date of ten years from the grant date. The exercise price is based on the share price the day prior to the grant.
- RELATED PARTY TRANSACTIONS
Martinrea is a shareholder of the Corporation with significant influence. Subsidiaries of Martinrea purchased graphene-enhanced products and tooling products from the Corporation during the three-month period ended September 30, 2026 for an amount of
$483,712 [As at June 30, 2026 - $533,794]. As at September 30, 2026, an amount of $290,656 due by Martinrea is included in Accounts receivable and contract assets [As at June 30, 2026 - $351,267].
- COMMITMENTS
As at September 30, 2026, the Corporation held forward exchange contracts to sell for a minimum of US$10.0 million and a maximum of US$15.3 million depending on the exchange rate of such derivative contracts. Rates vary from 1.352 to up to 1.403. The contracts are valid until March 2028. As at September 30, 2026, the carrying value of the derivative foreign currency forward exchange contracts of $466,302 is included in Accounts payable and accrued liabilities [As at June 30, 2026 - $413,820].
- SEGMENTED DISCLOSURE
The Corporation's Chief Operating Decision Maker analyzes the information for the Corporation on two reporting segments, based on products:
- Advanced Materials, Plastics and Composite Products:
Provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors.
- Battery Cells and Materials:
Provides silicon-graphene-enhanced Li-ion battery cells for the energy storage, industrial and defense markets.
The accounting policies of the segments are the same as the accounting policies of the Corporation.
Revenues and Expenses by operating segmentsFor the three-month periods ended September 30, 2026 and 2025:
2026 | Advanced Materials, Plastics and Compos ite Products $ | 2025 Battery Cells and Materials $ | Total $ | |||
Advanced Materials, Plastics and Battery Compos ite Cells and Products Materials $ $ | Total $ | |||||
Revenues | ||||||
Revenues from customers | 31,160,777 | - | 31,160,777 | 22,904,522 | 82,395 | 22,986,917 |
Other income | 324,341 | 328,695 | 653,036 | 259,014 | 196,720 | 455,734 |
31,485,118 | 328,695 | 31,813,813 | 23,163,536 | 279,115 | 23,442,651 | |
Cost of sales and expens es | ||||||
Cost of sales | 24,397,364 | - | 24,397,364 | 19,021,547 | - | 19,021,547 |
Research and development | ||||||
expenses and Selling, general and | 6,292,490 | 432,299 | 6,724,789 | 5,500,747 | 350,458 | 5,851,205 |
administrative expenses | ||||||
Share-based compensation expenses | 251,628 | - | 251,628 | 204,546 | - | 204,546 |
Depreciation and amortization | 2,929,135 | 413,116 | 3,342,251 | 2,541,901 | 413,415 | 2,955,316 |
Foreign exchange | 283,526 | 1,137 | 284,663 | (230,948) | (3,000) | (233,948) |
34,154,143 | 846,552 | 35,000,695 | 27,037,793 | 760,873 | 27,798,666 | |
Operating loss | (2,669,025) | (517,857) | (3,186,882) | (3,874,257) | (481,758) | (4,356,015) |
Net interest expenses | (687,297) | (8,734) | (696,031) | (329,957) | (6,854) | (336,811) |
Loss before income taxes | (3,356,322) | (526,591) | (3,882,913) | (4,204,214) | (488,612) | (4,692,826) |
Follow us
